Retatrutide/Cagrilintide Peptide For Sale
Buy Retatrutide/Cagrilintide peptide: 15mg, 22.5mg or 45mg listed purchase quantities. Compare live prices across 5 listed vendors with real cost per mg, recorded COA availability and discount codes.
Buy Retatrutide/Cagrilintide peptide starting at $98.99/purchase from 5 listed vendors. Compare 15mg, 22.5mg and 45mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).
How much does Retatrutide/Cagrilintide cost per month?
An illustrative Retatrutide/Cagrilintide cost model works out to about $21.10 per month: Southern Aminos's listed 45 mg purchase quantity at $109.65 with code WPA, divided into 2 mg amounts once weekly. This quantity provides 22.5 nominal portions — about 22.5 weeks at the selected cadence, before preparation losses or stability limits — for roughly $4.87 per week or $21.10 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 289 calculator runs; overall cadence comes from 67 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About Retatrutide/Cagrilintide
In clinical trialsAlso known as: Reta/Cagri stackRetatrutide/Cagrilintide is a research-only blend most often sourced for weight-loss and metabolic studies that pair incretin and amylin pharmacology in one protocol — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist retatrutide alongside Novo Nordisk's amylin analog cagrilintide. No sponsor markets it as a fixed-ratio drug; it ships as lyophilized powder you reconstitute with bacteriostatic water before use.[1][2]
What to check before you buy Retatrutide/Cagrilintide:
- A third-party COA that confirms BOTH peptides by mass spec — retatrutide (a 39-amino-acid triple agonist) and cagrilintide (an amylin analog) — at ≥98–99% purity by HPLC, since a blend can ship off-ratio or missing one component entirely.
- A COA dated within the last 6–12 months that matches the exact vial size, batch, and stated mg-per-peptide ratio you are buying.
- Accurate vial fill for each peptide: off-ratio or under-filled blend vials are a common failure mode and throw off every reconstitution and dosing calculation.
No randomized clinical trial of the retatrutide + cagrilintide combination has been published. The two molecules are studied separately: retatrutide in the TRIUMPH Phase 3 program for obesity and T2D,[1] and cagrilintide in the REDEFINE Phase 3 program as a fixed combination with semaglutide (CagriSema).[3] Any combined dosing protocol is extrapolated from the individual single-agent data.
Regulatory: Neither component is FDA-approved. Both are investigational; the fixed-ratio combination is not in any sponsor pipeline. Research-grade material only.
Retatrutide/Cagrilintide: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how Retatrutide/Cagrilintide works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
This is a research-only convenience blend pairing two long-acting metabolic peptides developed by different sponsors and never formulated, tested, or marketed as a fixed-ratio pharmaceutical product. Eli Lilly's investigational retatrutide is a single 39-amino-acid synthetic peptide that engages three different gut-hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor.[1][4] The GLP-1 arm slows gastric emptying and amplifies glucose-dependent insulin release; the GIP arm adds a second incretin signal that appears to amplify weight loss beyond pure GLP-1 agonism; and the glucagon arm — absent from semaglutide and tirzepatide — drives lipolysis in liver and adipose tissue and increases resting energy expenditure.[4][6] Novo Nordisk's cagrilintide is a long-acting acylated analog of pancreatic amylin that binds calcitonin/amylin-receptor heterodimers (AMY1–3) in the area postrema and hypothalamic arcuate nucleus, contributing a satiety signal that runs in parallel to — not through — the incretin pathway and that further slows gastric emptying.[2] Both molecules carry albumin-binding fatty-acid sidechains supporting once-weekly subcutaneous dosing (retatrutide ~6-day half-life, cagrilintide ~7-day half-life). Standalone Phase 2 dose ranges were 1–12 mg/week for retatrutide and 0.3–4.5 mg/week for cagrilintide.[1][2] **For the full mechanism and trial picture of each component, see the standalone Retatrutide and Cagrilintide deep dives — this blend page focuses on what is and is not known about the combination itself.**
Active research areas
- No head-to-head blend trial exists (the central caveat)No pharmaceutical sponsor is developing retatrutide + cagrilintide as a fixed-ratio product, and no randomised trial of the combination has been registered or published. All published incretin + amylin combination data come from the CagriSema program — semaglutide + cagrilintide, not retatrutide + cagrilintide — and cannot be directly extrapolated to a blend built on a triple agonist with a glucagon-receptor arm.[3][5]
- Retatrutide standalone evidence (TRIUMPH Phase 3)The flagship Phase 2 obesity trial reported mean weight reduction of approximately 24.2% at 48 weeks on the 12 mg arm — the largest figure published for any incretin therapy to date — and the Phase 3 TRIUMPH program is running confirmatory work in obesity, T2D, cardiovascular outcomes, and HFpEF.[1][7]
- Cagrilintide standalone evidence (Phase 2)The Phase 2 monotherapy trial in adults with overweight or obesity reported placebo-adjusted weight loss of roughly 6–8% at 26 weeks on the 2.4 mg/week dose, establishing amylin-receptor agonism as an independent satiety axis worth combining with incretin therapy.[2]
- Incretin + amylin combination class (CagriSema as proxy)Frias and colleagues' Phase 2 study of cagrilintide co-administered with semaglutide in T2D demonstrated additive effects on weight and A1C versus semaglutide alone,[5] and the REDEFINE Phase 3 program is the pivotal test of the incretin + amylin combination class — but specifically with semaglutide, not retatrutide.[3]
Open questions & leading hypotheses (2)
- Hypothesis: Adding cagrilintide to retatrutide produces additive weight loss beyond what high-dose retatrutide alone delivers.Evidence: Mechanistically the two molecules engage non-overlapping receptor systems, and the CagriSema (sema + cagri) Phase 2 data demonstrate genuine additivity of incretin + amylin in a related combination.[2][5] Counter-evidence: retatrutide monotherapy at 12 mg/week is already producing the largest weight-loss numbers in the field,[1] and the marginal contribution of an amylin analog on top of a triple agonist may be diminishing rather than additive; without a randomised reta+cagri trial this is purely inferential.
- Hypothesis: Co-administration of a high-dose triple agonist with an amylin analog is well-tolerated at the doses sold in research-grade blends.Evidence: Both molecules individually cause dose-dependent nausea, vomiting, and constipation in published trials,[1][2] and the standalone tolerability profiles are reasonably well-characterised in the Phase 2 record. Counter-evidence: gastric-emptying inhibition is additive across the two drug classes, no published trial has measured the combined GI-adverse-event rate, and the dose ratios sold by research-peptide suppliers are not anchored to any clinical-trial dataset.
What community users report
Anecdotal — not controlled-trial evidence
On r/Retatrutide and r/PeptideAdmin, users who run the blend most commonly do so by titrating retatrutide first (typically 2–4 mg/week ramped over 4–8 weeks) and then layering in low-dose cagrilintide (0.3–0.6 mg/week ramped slowly), usually citing additive appetite suppression and a smoother satiety curve through the week as the rationale.[8][9] Reported side effects mirror the standalone profiles — nausea, constipation, and occasional reflux — with several threads describing the combined GI burden as meaningfully greater than retatrutide alone, prompting users to back off cagrilintide before retatrutide. **All community reports are anecdotal and have not been validated in controlled trials.** Because no head-to-head reta + cagri trial exists, every claim about additive efficacy, optimal dose ratio, or relative tolerability of the blend is currently speculative.
Sources & references (9)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514–526. · PMID: 37366315 link
- [2]Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: phase 2 trial. Lancet 2021;398:2160–2172. · PMID: 34798060 link
- [3]ClinicalTrials.gov: REDEFINE 1 (NCT05567796) — CagriSema in adults with overweight or obesity. link
- [4]Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 2022;34:1234–1247.e9. · PMID: 35985340 link
- [5]Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023;402:720–730. · PMID: 37364590 link
- [6]Müller TD et al. The new biology and pharmacology of glucagon. Physiol Rev 2017;97:721–766. · PMID: 28275047 link
- [7]ClinicalTrials.gov: TRIUMPH-1 (NCT05929066) — Phase 3 retatrutide in adults with obesity. link
- [8]Community report — r/Retatrutide cagrilintide-stack threads (subreddit), accessed May 2026. link
- [9]Community report — r/PeptideAdmin retatrutide + cagrilintide protocol discussions (subreddit), accessed May 2026. link
What Retatrutide/Cagrilintide Costs Right Now
WPA currently tracks Retatrutide/Cagrilintide from 5 distinct vendors. In-stock Retatrutide/Cagrilintide vials run from $98.99 to $126.65 — a 1.3x spread for the same compound. Modified Aminos holds the lowest sticker price at $98.99. Normalized to milligrams, Retatrutide/Cagrilintide costs $2.44/mg to $7.08/mg on this page. The best per-milligram value is the listed 45 mg purchase quantity from Southern Aminos.
Retatrutide/Cagrilintide is stocked in 3 sizes: 15 mg listed quantity; vial count not recorded; 45 mg listed quantity; vial count not recorded; 22.5 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the Retatrutide/Cagrilintide listings WPA tracks are: Southern Aminos — 45mg at $109.65 ($2.44/mg), COA purity 99.61%; Flawless Compounds — 22.5mg at $126.65 ($5.63/mg), COA purity 99.90%; Glow Aminos — 22.5mg at $126.65 ($5.63/mg), COA purity 99.98%; Modified Aminos — 15mg at $98.99 ($6.60/mg), COA purity 99.00%; EZ Peptides — 15mg at $106.20 ($7.08/mg).
Retatrutide/Cagrilintide COA Coverage Across Tracked Vendors
5 of the 5 tracked Retatrutide/Cagrilintide listings (100%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 4 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.00% to 99.98%. 5 listings record more Retatrutide/Cagrilintide in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 9/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Retatrutide/Cagrilintide offer. WPA's listing fields do not establish that a report was independently verified.
Retatrutide/Cagrilintide Calculator Input Observations
In lifetime Retatrutide/Cagrilintide calculator inputs, 2mg is the most frequent entered amount (60 of 289 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (50 of 65 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 2mg, Weekly (1x/wk) is most frequent (12 of 19 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 45 mg of listed product divided by 2 mg gives roughly 23 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
Retatrutide/Cagrilintide Discount Codes
5 of the 5 tracked Retatrutide/Cagrilintide listings carry a WPA researcher discount code. The largest live discount is 15% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About Retatrutide/Cagrilintide
Retatrutide/Cagrilintide is a research-only blend most often sourced for weight-loss and metabolic studies that pair incretin and amylin pharmacology in one protocol — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist retatrutide alongside Novo Nordisk's amylin analog cagrilintide. No sponsor markets it as a fixed-ratio drug; it ships as lyophilized powder you reconstitute with bacteriostatic water before use.
Retatrutide/Cagrilintide is a blend of Cagrilintide and Retatrutide, so a COA has to confirm each component separately — a single purity figure for the mixture is not enough. Its reported half-life is ~6 days (retatrutide-driven). Calculator inputs do not establish why a cadence was selected or validate a protocol. Neither component is FDA-approved.
How to Read the Retatrutide/Cagrilintide Comparison
- Price per milligram — Every Retatrutide/Cagrilintide listing is normalized to $2.44/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 5 Retatrutide/Cagrilintide listings are marked for COA availability, and 4 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The Retatrutide/Cagrilintide comparison includes 15mg, 22.5mg, and 45mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each Retatrutide/Cagrilintide listing, refreshed on a recurring basis.
Frequently Asked Questions: Retatrutide/Cagrilintide
Is it legal and safe to buy Retatrutide/Cagrilintide Blend for research?
In the US, Retatrutide/Cagrilintide Blend is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. Both peptides are investigational with no approved human form, and the pre-combined blend is sold for laboratory use only. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 5 Retatrutide/Cagrilintide Blend listings from 5 vendors.
How do I verify a Retatrutide/Cagrilintide Blend COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific Retatrutide/Cagrilintide Blend batch. Check that the report identifies the compound (both retatrutide and cagrilintide at the labeled ratio, not just one of the two or an underdosed mix), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Retatrutide/Cagrilintide Blend specifically, 5 of 5 tracked listings (100%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 4 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 9/26.
Which Retatrutide/Cagrilintide Blend vendor should I pick?
There's no single "best" Retatrutide/Cagrilintide Blend vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. For a blend, COA identity matters double — a good vendor's COA confirms both peptides are present at the stated amounts, and blend ratios drift if formulation isn't tightly controlled. 5 vendors currently carry Retatrutide/Cagrilintide Blend, and Southern Aminos holds the best true value at $2.44/mg on the 45 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does Retatrutide/Cagrilintide Blend cost — and how do I know I'm not overpaying?
Judge Retatrutide/Cagrilintide Blend by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It is usually sold as a single combined vial, and buying the two peptides pre-blended is normally cheaper than sourcing them separately. Tracked Retatrutide/Cagrilintide Blend listings currently run $2.44/mg to $7.08/mg across 15mg, 22.5mg, 45mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much Retatrutide/Cagrilintide Blend do I need for one full cycle?
In lifetime Retatrutide/Cagrilintide Blend calculator inputs, 2mg is the most frequent entered amount (60 of 289 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (50 of 65 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 2mg, Weekly (1x/wk) is most frequent (12 of 19 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 45 mg purchase quantity by 2 mg gives roughly 23 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for Retatrutide/Cagrilintide Blend?
Participating Retatrutide/Cagrilintide Blend vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 5 of the 5 tracked Retatrutide/Cagrilintide Blend listings carry a code right now, the largest worth 15% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
Where can I compare Retatrutide/Cagrilintide prices and listing details?
This comparison shows 5 tracked listings for Retatrutide/Cagrilintide in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.